Esperion Therapeutics (NASDAQ:ESPR) reported a significant increase in first-quarter revenues, reaching $137.74 million, a 467% increase year-over-year, and surpassing consensus estimates of $84.51 million. The company also reported an EPS of $0.34, beating the consensus of $0.05 and marking a turnaround from a loss of $(0.79) a year ago. The revenue boost was attributed to U.S. net product revenue growth of 46% Y/Y and collaboration revenue of $113.0 million, driven by increased tablet sales and a settlement-related milestone payment. The FDA approved new label expansions for NEXLETOL and NEXLIZET tablets, and the company has initiated commercial initiatives to increase patient awareness. Esperion also began the technology transfer process for tablet manufacturing to Daiichi Sankyo Europe and authorized commercialization of a new triple formulation product. The company expects FY 2024 operating expenses to be between $225 million and $245 million. ESPR shares rose 5.20% to $2.23.